centerforbiosimilars18h
Gary Fanjiang, MD, MBA, MS
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars1d
The Top 5 Biosimilar Articles for the Week of September 16
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
centerforbiosimilars2d
Stacie Ropka, JD, PhD
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars3d
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
centerforbiosimilars3d
Christina Corridon, MPH, MBA
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars3d
Jeff Patton, MD
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars4d
FDA Approves Pavblu for Retinal Conditions
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
centerforbiosimilars4d
Ashley Gallagher
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars5d
Expanding Biosimilar Adoption: Insights and Strategies with Dr Sophia Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...